NASDAQ:MXCT MaxCyte (MXCT) Stock Price, News & Analysis → How’d you do in 2022 (From Brooks Enterprises) (Ad) Free MXCT Stock Alerts $4.83 +0.24 (+5.23%) (As of 06/6/2024 ET) Add Compare Share Share Today's Range$4.59▼$5.0150-Day Range$3.63▼$4.8352-Week Range$2.45▼$5.55Volume657,065 shsAverage Volume586,950 shsMarket Capitalization$504.25 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MaxCyte alerts: Email Address MaxCyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside79.4% Upside$8.67 Price TargetShort InterestHealthy3.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$22,050 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.51) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.79 out of 5 starsMedical Sector598th out of 905 stocksCommercial Physical Research Industry8th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingMaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMaxCyte has only been the subject of 3 research reports in the past 90 days.Read more about MaxCyte's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.79% of the float of MaxCyte has been sold short.Short Interest Ratio / Days to CoverMaxCyte has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in MaxCyte has recently decreased by 2.79%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MXCT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for MaxCyte this week, compared to 1 article on an average week.Search Interest4 people have searched for MXCT on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,050.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MaxCyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to grow in the coming year, from ($0.51) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -13.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -13.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MaxCyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingA New Generation of Billionaires Is About to Be CreatedOn June 30, AI will hit a tipping-point… $15.7 trillion of wealth is at stake. As many as 800 million jobs are caught in AI’s crosshairs…Click here for details. About MaxCyte Stock (NASDAQ:MXCT)MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Read More MXCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXCT Stock News HeadlinesMay 29, 2024 | globenewswire.comMaxCyte to Participate in William Blair 44th Annual Growth Stock ConferenceMay 22, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentMay 8, 2024 | lse.co.ukMaxCyte shares rise amid double-digit revenue increaseMay 8, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 7, 2024 | investorplace.comMXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 3, 2024 | morningstar.comMaxCyte Inc MYE0April 26, 2024 | finance.yahoo.comMaxCyte, Inc. (MXCT)April 10, 2024 | globenewswire.comMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024April 5, 2024 | msn.comMesa Laboratories maintains quarterly dividend of $0.16April 2, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)March 17, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermMarch 15, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 14, 2024 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 13, 2024 | marketwatch.comMaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 6, 2024 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsFebruary 9, 2024 | finance.yahoo.comMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersJanuary 23, 2024 | markets.businessinsider.comMaxCyte Signs SPL Agreement With ImugeneJanuary 9, 2024 | msn.comWhy Cell Engineering Company MaxCyte Shares Are Up TodaySee More Headlines Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/07/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:MXCT CUSIPN/A CIK1287098 Webmaxcyte.com Phone301-944-1700Fax301-944-1703Employees143Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$11.00 Low Stock Price Target$7.00 Potential Upside/Downside+79.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,920,000.00 Net Margins-83.00% Pretax Margin-83.00% Return on Equity-15.68% Return on Assets-13.74% Debt Debt-to-Equity RatioN/A Current Ratio13.26 Quick Ratio12.37 Sales & Book Value Annual Sales$41.29 million Price / Sales12.21 Cash FlowN/A Price / Cash FlowN/A Book Value$2.23 per share Price / Book2.17Miscellaneous Outstanding Shares104,400,000Free Float101,264,000Market Cap$504.25 million OptionableOptionable Beta1.45 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Douglas Arthur Doerfler (Age 68)Founder Comp: $2.34MMr. Douglas J. Swirsky CFA (Age 55)CPA, Chief Financial Officer Comp: $607.42kMr. Jay GelfmanSenior Vice President of OperationsMr. Ronald Evan Holtz CPA (Age 66)Ph.D., Executive Vice President of Administration Comp: $649.38kKey CompetitorsHeron TherapeuticsNASDAQ:HRTXMeiraGTxNASDAQ:MGTXAnaptysBioNASDAQ:ANABNational ResearchNASDAQ:NRCOmniAbNASDAQ:OABIView All CompetitorsInsiders & InstitutionsSwedbank ABBought 1,600,000 shares on 5/21/2024Ownership: 1.531%Silvercrest Asset Management Group LLCBought 30,209 shares on 5/16/2024Ownership: 0.669%Grandeur Peak Global Advisors LLCSold 406,173 shares on 5/16/2024Ownership: 0.240%California State Teachers Retirement SystemSold 4,474 shares on 5/16/2024Ownership: 0.084%Price T Rowe Associates Inc. MDBought 4,320 shares on 5/15/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions MXCT Stock Analysis - Frequently Asked Questions Should I buy or sell MaxCyte stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MXCT shares. View MXCT analyst ratings or view top-rated stocks. What is MaxCyte's stock price target for 2024? 4 brokers have issued 1 year target prices for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $11.00. On average, they predict the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 79.4% from the stock's current price. View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts. How have MXCT shares performed in 2024? MaxCyte's stock was trading at $4.70 at the start of the year. Since then, MXCT stock has increased by 2.8% and is now trading at $4.83. View the best growth stocks for 2024 here. When is MaxCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our MXCT earnings forecast. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.05. The company earned $11.34 million during the quarter, compared to the consensus estimate of $7.75 million. MaxCyte had a negative trailing twelve-month return on equity of 15.68% and a negative net margin of 83.00%. When did MaxCyte IPO? MaxCyte (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share. Who are MaxCyte's major shareholders? MaxCyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.11%), River Global Investors LLP (1.81%), Swedbank AB (1.53%), Chevy Chase Trust Holdings LLC (1.24%), Silvercrest Asset Management Group LLC (0.67%) and Blue Water Life Science Advisors LP (0.58%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross. View institutional ownership trends. How do I buy shares of MaxCyte? Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MXCT) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.